EUVIMEDEUVIMED entdecken
Crossref

Dual-Targeting Nanoplatform to Regulate Metabolic Disorders: From Obesity to Obesity-Related Metabolic Dysfunction-Associated Steatotic Liver Disease

Qiaqia Xiao, Chuying Wang, Jing Yang, Xueyu Gao, Zhaoan Chen, Zheming Niu, Yi Hou iD, Cong Fu, Ziwei Yan, Guangda Zhu iD, Hening Liu, Yue Yin und 3 weitere

Nano Letters · 22.10.2025 · 25 (42) · 15416-15427

DOI: 10.1021/acs.nanolett.5c04561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, online erschienen am 08.10.2025. Verfasst von Qiaqia Xiao und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. Ch…. Hauptthemen laut MEDLINE: Obesity, Fatty Liver, Resveratrol, Metabolic Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Nature Science Foundation of China, Six Talent Peaks Project in Jiangsu Province, ?333 Project? of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity manifests as excessive fat storage within adipose tissue (AT) and is often accompanied by insulin resistance, which can initiate the development of obesity-related metabolic dysfunction-associated steatotic liver disease (MASLD). Herein, a dual-targeting drug delivery system is designed to regulate these metabolic disorders by alleviating aberrant fat accumulation and anti-inflammation. Specifically, polymetformin (P) and resveratrol (R), two therapeutic agents that show preferable antiadiposity effect, are co-loaded in macrophage-disguised and apolipoprotein A-I (apoA-I)-decorated liposome (aML/R&P). Mechanistically, P and R can upregulate uncoupling protein 1 (UCP1) expression to promote AT browning and enhance hepatocyte autophagy to ameliorate hepatic steatosis and inflammation. Meanwhile, the dual modification of macrophage membrane and apoA-I largely improves its targeting efficiency toward liver and AT. In mouse models of obesity and MASLD, aML/R&P effectively reduces body weight, restores metabolic homeostasis, enhances liver parameters, and improves insulin sensitivity, demonstrating great promise in treating obesity and obesity-associated metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityFatty LiverResveratrolMetabolic DiseasesAnimalsMiceLiposomesHumansMacrophagesApolipoprotein A-IDrug Delivery SystemsInsulin ResistanceMice, Inbred C57BLLiverMaleUncoupling Protein 1

Stichwörter der Autor:innen

drug deliveryenergy expendituremetabolic regulationnanotechnologyobesity

Substanzen

LiposomesResveratrolApolipoprotein A-IUncoupling Protein 1

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China.
  • NMPA Key Laboratory for Research and Evaluation of Cosmetics, China Pharmaceutical University, Nanjing 211198, P. R. China.
  • Institute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn 53127, Germany.
  • Leibniz-Institut für Polymerforschung Dresden e.V., Dresden 01069, Germany.
  • Research Center for Materials, Architectures, and Integration of Nanomembranes (Main), TU Chemnitz, Chemnitz 09126, Germany.
  • School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China.

ORCID-Profile: Yi Hou, Guangda Zhu, Wei Wang

Förderung

  • National Nature Science Foundation of China
  • Six Talent Peaks Project in Jiangsu Province
  • ?333 Project? of Jiangsu Province
  • Alexander von Humboldt-Stiftung
  • National Natural Science Foundation of China

Zitieren

APA

Xiao, Q., Wang, C., Yang, J., Gao, X., Chen, Z., Niu, Z., Hou, Y., Fu, C., Yan, Z., Zhu, G., Liu, H., Yin, Y., Shang, J., Wang, W., & Tang, L. (2025). Dual-Targeting Nanoplatform to Regulate Metabolic Disorders: From Obesity to Obesity-Related Metabolic Dysfunction-Associated Steatotic Liver Disease. Nano Letters, 25(42), 15416-15427. https://doi.org/10.1021/acs.nanolett.5c04561

Vancouver

Xiao Q, Wang C, Yang J, Gao X, Chen Z, Niu Z, et al. Dual-Targeting Nanoplatform to Regulate Metabolic Disorders: From Obesity to Obesity-Related Metabolic Dysfunction-Associated Steatotic Liver Disease. Nano Letters. 2025;25(42):15416-15427. doi:10.1021/acs.nanolett.5c04561

BibTeX
@article{Xiao2025,
  author = {Xiao, Qiaqia and Wang, Chuying and Yang, Jing and Gao, Xueyu and Chen, Zhaoan and Niu, Zheming and Hou, Yi and Fu, Cong and Yan, Ziwei and Zhu, Guangda and Liu, Hening and Yin, Yue and Shang, Jing and Wang, Wei and Tang, Lu},
  title = {Dual-Targeting Nanoplatform to Regulate Metabolic Disorders: From Obesity to Obesity-Related Metabolic Dysfunction-Associated Steatotic Liver Disease},
  journal = {Nano Letters},
  year = {2025},
  volume = {25},
  number = {42},
  pages = {15416--15427},
  doi = {10.1021/acs.nanolett.5c04561}
}
Kostenlos starten →